Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and Efficacy
Claire N. Harrison, Jacqueline S. Garcia, Tim C.P. Somervaille, James M. Foran, Srdan Verstovsek, Catriona Jamieson, Ruben Mesa, Ellen K. Ritchie, Srinivas K. Tantravahi, Pankit Vachhani, Casey L. O'Connell, Rami S. Komrokji, Jason Harb, Jessica E. Hutti, Leanne Holes, Abdullah A. Masud, Silpa Nuthalapati, Jalaja Potluri, Naveen Pemmaraju
Profundice en los temas de investigación de 'Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients with Myelofibrosis with Progression or Suboptimal Response: Phase II Safety and Efficacy'. En conjunto forman una huella única.